PARMAR KUSH — SEC Form 4 filings
SEC reporting owner CIK 1664281. 22 Form 4 filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2024-02-02 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 5 filings — 10,339,673 shares, $41,026,016 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 39 legs across 11 filings — 2,856,203 shares, $27,263,599 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: purchase of 5,206,074 shares @ $2.31 ($12,026,031) in Skye Bioscience, Inc., filed 2024-02-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 10% owner | 2 | — | 4 legs · 1,325,000 sh · $19,792,500 | — |
| Skye Bioscience, Inc. (SKYE) | 10% owner | 6 | 2 legs · 5,656,074 sh · $16,526,031 | 21 legs · 907,474 sh · $2,755,947 | — |
| Camp4 Therapeutics Corp (CAMP) | 10% owner | 3 | 2 legs · 3,850,266 sh · $14,499,989 | — | 6 |
| Artiva Biotherapeutics, Inc. (ARTV) | 10% owner | 1 | 1 leg · 833,333 sh · $9,999,996 | — | 5 |
| Entrada Therapeutics, Inc. (TRDA) | Director | 8 | — | 14 legs · 623,729 sh · $4,715,151 | 3 |
| Latigo Biotherapeutics, Inc. (LTGO) | 10% owner | 1 | — | — | 6 |
| Rallybio Corp (RLYB) | Director | 1 | — | — | 1 |
Form 4 filings — PARMAR KUSH
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 32,607 @ $1.91 · Sale (S): 1,285 @ $1.91 | EDGAR |
| 2026-08-20 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 45,090 @ $0.38 · Sale (S): 1,830 @ $0.38 · Sale (S): 253,080 @ $0.38 · Sale (S): 10,255 @ $0.35 · Sale (S): 409 @ $0.35 · Sale (S): 57,476 @ $0.35 · +3 more | EDGAR |
| 2026-08-12 | 4 | Latigo Biotherapeutics, Inc. (LTGO) jointly with 5AM Ventures VI, L.P., 5AM Partners VI, LLC, 5AM Opportunities II, L.P., 5AM Opportunities II (GP), LLC, Schwab Andrew J. | Conversion (C): 4,975,543 · Conversion (C): 2,350,419 · Conversion (C): 3,152,305 (derivative) @ $0 · Conversion (C): 1,823,238 (derivative) @ $0 · Conversion (C): 866,018 (derivative) @ $0 · Conversion (C): 1,484,401 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 10,494 @ $7 · Sale (S): 52,317 @ $6.85 · Sale (S): 92,444 @ $7 | EDGAR |
| 2026-08-05 | 4 | Camp4 Therapeutics Corp (CAMP) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., 5AM Partners VII, LLC, 5AM Ventures VII, L.P. | Purchase (P): 3,179,558 (derivative) @ $1.53 | EDGAR |
| 2026-08-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 114,756 @ $6.93 · Sale (S): 1,718 @ $6.85 | EDGAR |
| 2026-06-12 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 200,000 @ $8.80 | EDGAR |
| 2025-09-15 | 4 | Camp4 Therapeutics Corp (CAMP) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., 5AM Partners VII, LLC, 5AM Ventures VII, L.P. | Purchase (P): 2,941,176 @ $1.53 | EDGAR |
| 2025-08-22 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 58,642 @ $3.57 · Sale (S): 2,314 @ $3.57 · Sale (S): 163,979 @ $3.42 · Sale (S): 6,470 @ $3.42 | EDGAR |
| 2025-07-11 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 20,065 @ $7.50 · Sale (S): 6,935 @ $7.50 | EDGAR |
| 2025-07-01 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 55,735 @ $6.91 · Sale (S): 19,265 @ $6.91 · Sale (S): 18,578 @ $6.81 · Sale (S): 6,422 @ $6.81 · Sale (S): 18,578 @ $7.12 · Sale (S): 6,422 @ $7.12 | EDGAR |
| 2025-06-12 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-10-15 | 4 | Camp4 Therapeutics Corp (CAMP) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P. | Conversion (C): 1,716,055 · Conversion (C): 302,770 · Purchase (P): 909,090 @ $11 · Conversion (C): 15,002,166 (derivative) · Conversion (C): 4,244,770 (derivative) · Conversion (C): 3,395,816 (derivative) | EDGAR |
| 2024-09-13 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Sale (S): 214,556 @ $6.60 · Sale (S): 36,504 @ $6.60 · Sale (S): 1,440 @ $6.60 · Sale (S): 11,758 @ $6.06 · Sale (S): 2,000 @ $6.06 · Sale (S): 79 @ $6.06 | EDGAR |
| 2024-07-24 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., Schwab Andrew J. | Conversion (C): 1,058,284 · Other (J): 112,966 @ $10.20 · Other (J): 348,721 @ $10.20 · Purchase (P): 833,333 @ $12 · Conversion (C): 843,592 (derivative) · Conversion (C): 214,692 (derivative) | EDGAR |
| 2024-06-14 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Purchase (P): 450,000 @ $10 | EDGAR |
| 2024-02-16 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., Schwab Andrew J. | Sale (S): 688,358 @ $14.90 · Sale (S): 136,642 @ $14.90 | EDGAR |
| 2024-02-02 | 4 | Skye Bioscience, Inc. (SKYE) jointly with 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, ROCKLAGE SCOTT M | Purchase (P): 5,206,074 @ $2.31 | EDGAR |
| 2024-02-02 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., Schwab Andrew J. | Sale (S): 417,187 @ $15 · Sale (S): 82,813 @ $15 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1664281 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →